How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Genetically Modified Rat Market
- By Genetic Modification Technique: CRISPR/Cas9, Zinc Finger Nucleases (ZFNs), Transgenic Technology, RNA Interference (RNAi), TALENs
- By Rat Strain: Sprague Dawley, Wistar, Long Evans, Fischer 344, Lewis
- By Application: Pharmaceutical Research, Toxicology Studies, Oncology Research, Neurological Disease Modeling, Cardiovascular Research
- By Product Type: Knockout Rats, Knockin Rats, Transgenic Rats, Humanized Rats, Conditional Knockout Rats
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - CRISPR/Cas9 leads By Genetic Modification Technique at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 10 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Genetically Modified Rat Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Genetic Modification Technique 5
Rat Strain 5
Application 5
Product Type 5
Companies profiled
Charles River Laboratories
Taconic Biosciences
Envigo (a part of Inotiv)
The Jackson Laboratory
Crown Bioscience
Cyagen Biosciences
GenOway
SAGE Labs
Oriental BioService
Biocytogen
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Charles River Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Taconic Biosciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Envigo (a part of Inotiv)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →The Jackson Laboratory
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Crown Bioscience
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Cyagen Biosciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →GenOway
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →SAGE Labs
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Oriental BioService
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Biocytogen
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,646M by 2033 · 7.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- CRISPR/Cas947.5
- Zinc Finger Nucleases (ZFNs)9.5
- Transgenic Technology21.0
- RNA Interference (RNAi)9.3
- TALENs12.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$507.2M → $808.4M · 6.0%
Europe$353.5M → $659.8M · 8.1%
Asia Pacific$322.7M → $609.3M · 8.3%
Latin America$199.8M → $309.8M · 5.6%
Middle East and Africa$153.7M → $279.9M · 7.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.982026
7.002027
7.012028
7.012029
7.032030
7.042031
7.052032
7.062033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Charles River Laboratories19.4
- Taconic Biosciences17.9
- Envigo (a part of Inotiv)5.1
- The Jackson Laboratory5.6
- Crown Bioscience14.2
- Cyagen Biosciences9.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Genetic Modification Technique25.3%
Rat Strain31.3%
Application10.9%
Product Type32.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.3
- Europe24.7
- Asia Pacific22.8
- Latin America11.6
- Middle East and Africa10.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories | 73 | 73 | 76 | 76 | 95 | 90 | 81 |
| Taconic Biosciences | 75 | 78 | 86 | 68 | 86 | 82 | 79 |
| Envigo (a part of Inotiv) | 66 | 83 | 83 | 64 | 81 | 85 | 77 |
| The Jackson Laboratory | 66 | 64 | 76 | 57 | 57 | 78 | 66 |
| Crown Bioscience | 54 | 72 | 53 | 63 | 70 | 65 | 63 |
| Cyagen Biosciences | 59 | 58 | 66 | 65 | 55 | 54 | 60 |
| GenOway | 48 | 55 | 47 | 51 | 54 | 42 | 50 |
| SAGE Labs | 48 | 43 | 43 | 50 | 45 | 60 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Charles River Laboratories
- Taconic Biosciences
- Envigo (a part of Inotiv)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Charles River Laboratories | ◐ | − | − | ◐ | ◐ | ✓ |
| Taconic Biosciences | − | ✓ | ✓ | ◐ | ✓ | ✓ |
| Envigo (a part of Inotiv) | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| The Jackson Laboratory | − | ✓ | ◐ | ◐ | − | ◐ |
| Crown Bioscience | ◐ | ✓ | − | − | ◐ | ◐ |
| Cyagen Biosciences | − | − | ◐ | ◐ | − | ◐ |
| GenOway | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| SAGE Labs | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Charles River Laboratories81
2Taconic Biosciences79
3Envigo (a part of Inotiv)77
4The Jackson Laboratory66
5Crown Bioscience63
6Cyagen Biosciences60
7GenOway50
8SAGE Labs48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Charles River LaboratoriesTaconic Biosciences
Challenger1
Strong scale, closing on the leaders.
Envigo (a part of Inotiv)
Contender3
Focused players with pockets of strength.
The Jackson LaboratoryCrown BioscienceCyagen Biosciences
Niche2
Specialists in a single segment or region.
GenOwaySAGE Labs
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Genetic Modification Technique in North America, then scale across Genetically Modified Rat Market — a $233M beachhead inside a $3.44B market.
Beachhead (SOM)$233Mobtainable near-term
Serviceable (SAM)$1.25Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
CRISPR/Cas9
Best fit — highest urgency & budget in Genetic Modification Technique.
Economic buyer80 fit
Zinc Finger Nucleases (ZFNs)
Strong fit — clear ROI and a fast path to value.
End user65 fit
Transgenic Technology
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Genetic Modification Technique in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Rat Strain & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel26%
Digital / self-serve19%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Genetic Modification Technique leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Genetically Modified Rat Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified26%
Evaluation13%
Closed-won7%
$11.4KCAC
$56KLTV
4.9:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Genetically Modified Rat Market is a durable-growth opportunity — $5.36B by 2033, compounding at 7.2%.
TAM · 2025$3.08Btoday
TAM · 2033$5.36Bforecast
CAGR7.2%2027–2033
Cumulative$37.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.36BTotal addressable market
SAM$2.23BServiceable available market
SOM$395MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.2% CAGR
Demand compounds through 2033, outpacing GDP across Genetic Modification Technique.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Genetic Modification Technique moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.36BLarge & growingTAM by 2033 at 7.2% CAGR
$2.23BServiceable nowreachable with today’s model
$395MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.18BBear4.7% CAGR
$5.36BBase7.2% CAGR
$6.87BBull9.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Rat Strain optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Genetically Modified Rat Market — a $4.11B market by 2033. Plan: grow share from 7.8% to 12.8%.
Market size · 2033$4.11Btotal addressable
Market CAGR3.3%2027–2033
Target share12.8%from 7.8% today
Revenue ambition$526Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.8% | 12.8% | Behind |
| Revenue | $330M | $526M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 31.4% | 39.0% | Ahead |
| Customer retention | 91.4% | 93.5% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Genetic Modification Technique
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Rat Strain capability
A defensible second engine — invest in Rat Strain to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Genetic Modification Technique share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Rat Strain
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $78M capacity & capability investment
- Greenlight bolt-on M&A in Rat Strain
- Authorise North America expansion plan
- Fund R&D program for Genetic Modification Technique leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Genetically Modified Rat Market conversation — a $7.07B market you can size, segment and defend in minutes.
Market size · 2033$7.07Btotal opportunity
Growth7.4%CAGR to 2033
Addressable buyers1,749+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Genetic Modification Technique
Goal Grow share in Genetic Modification Technique
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 3 mopayback period
$93K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Charles River LaboratoriesTaconic BiosciencesEnvigo (a part of Inotiv)The Jackson LaboratoryCrown BioscienceCyagen BiosciencesGenOwaySAGE Labs+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Genetically Modified Rat Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Genetically Modified Rat Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Genetically Modified Mouse Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportGenetically Modified Drug Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportLions Mane Mushroom Extract Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportGenetically Modified Animal Model Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportGenetically Engineered Vaccines Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportGenetically Engineered Mouse Model (GEMM) Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportGene Therapy Viral Vector and Plasmid DNA Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportGene Therapy Products Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportGene Therapy on Neurological Diseases Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportGene Therapy On Cardiovascular Disease Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportGene Therapy on Cancer Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportGene Therapy Medicine Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.